Tivozanib: a novel VGFR inhibitor for kidney cancer

Helen Boyle


Treatment of kidney cancer has changed over the past 10 years with the approval of several targeted agents. These drugs are given on a long term base and toxicity is an issue for most patients. Despite improvement compared to immunotherapy, most patients will progress on these drugs. There is a need for more portent and better tolerated drugs. Tivozanib is a potent pan VEGR specific inhibitor. In this phase II trial it gave interesting results with an overall median PFS throughout the study of 11.7 months (95% IC: 8.3-14.3 months) and an overall objective response rate of 24% (95% IC: 19-30%). “Off”-target toxicity was mild.